Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Clinical trial NCT06192784 · UNKNOWN
Trial details
- NCT number
- NCT06192784
- Sponsor
- Tongji Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-09
- Primary completion
- 2025-01-31
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.